KRAS and lung adenocarcinoma: The first-line Bevacizumad and platinum based chemotherapy for patients with advanced lung adenocarcinoma, the patients with KRASG12D mutation had significantly poorPFS and OS than patients with wild-type KRAS or other KRAS mutations [21].